Cargando…
A Response to: Letter to the Editor Regarding ‘Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland’
Autores principales: | Aksan, Aysegül, Schoepfer, Alain, Juillerat, Pascal, Vavricka, Stephan, Bettencourt, Miguel, Ramirez de Arellano, Antonio, Gavata, Simona, Morin, Neige, Valentine, William J., Hunt, Barnaby |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799560/ https://www.ncbi.nlm.nih.gov/pubmed/34846708 http://dx.doi.org/10.1007/s12325-021-02001-4 |
Ejemplares similares
-
Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland
por: Aksan, Aysegül, et al.
Publicado: (2020) -
Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK
por: Aksan, Aysegül, et al.
Publicado: (2021) -
Letter to the Editor Regarding ‘Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland’
por: Muñoz, Manuel, et al.
Publicado: (2021) -
Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Aksan, Ayşegül, et al.
Publicado: (2019) -
Cost-effectiveness analysis of ferric carboxymaltose
versus iron sucrose for the treatment of iron deficiency
anemia in patients with inflammatory bowel disease in Spain
por: Argüelles-Arias, Federico, et al.
Publicado: (2022)